Pharmacokinetics of linezolid in septic patients with and without extended dialysis
Linezolid is an option for the treatment of infections caused by multiresistant Gram-positive bacteria. The survival of critically ill patients with acute renal failure (ARF) can be improved by increasing the dose of renal replacement therapy. Extended (daily) dialysis (ED) is a new and important ap...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2010
|
| In: |
European journal of clinical pharmacology
Year: 2010, Volume: 66, Issue: 3, Pages: 291-298 |
| ISSN: | 1432-1041 |
| DOI: | 10.1007/s00228-009-0766-9 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00228-009-0766-9 |
| Author Notes: | Stefanie Swoboda, Michael C. Ober, Christoph Lichtenstern, Soundos Saleh, Vedat Schwenger, Hans-Günther Sonntag, Walter Emil Haefeli, Georg Hempel, Torsten Hoppe-Tichy, Markus A. Weigand |
| Summary: | Linezolid is an option for the treatment of infections caused by multiresistant Gram-positive bacteria. The survival of critically ill patients with acute renal failure (ARF) can be improved by increasing the dose of renal replacement therapy. Extended (daily) dialysis (ED) is a new and important approach to renal replacement therapy in intensive care units. The aim of the study was to evaluate the pharmacokinetics of linezolid in septic patients without ED and on ED, respectively. |
|---|---|
| Item Description: | Erstmals am 16 December 2009 online veröffentlicht Gesehen am 06.09.2023 |
| Physical Description: | Online Resource |
| ISSN: | 1432-1041 |
| DOI: | 10.1007/s00228-009-0766-9 |